Orchestra BioMed (NASDAQ:OBIO) Insider David Hochman Purchases 5,000 Shares

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) insider David Hochman purchased 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average price of $3.77 per share, for a total transaction of $18,850.00. Following the purchase, the insider directly owned 1,059,029 shares in the company, valued at $3,992,539.33. The trade was a 0.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Orchestra BioMed Price Performance

Shares of NASDAQ:OBIO opened at $4.00 on Wednesday. The company has a market capitalization of $239.52 million, a PE ratio of -4.12 and a beta of 0.52. The company has a debt-to-equity ratio of 0.35, a current ratio of 7.03 and a quick ratio of 7.01. Orchestra BioMed Holdings, Inc. has a 1-year low of $2.20 and a 1-year high of $5.42. The business has a fifty day moving average price of $4.27 and a 200-day moving average price of $4.27.

Orchestra BioMed (NASDAQ:OBIO) last issued its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.07. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.92 million. As a group, equities analysts expect that Orchestra BioMed Holdings, Inc. will post -1.54 EPS for the current fiscal year.

Key Orchestra BioMed News

Here are the key news stories impacting Orchestra BioMed this week:

• Positive Sentiment: Multiple insiders bought shares, including Director Eric Fain’s purchase of 20,000 shares and additional buying by David P. Hochman and Jason Aryeh. Insider buying is often read as a vote of confidence in the company’s outlook. SEC filing for Eric Fain purchase
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $10 price target, while slightly raising near-term and FY2026 earnings estimates. That suggests analysts still see meaningful upside from current levels. Benzinga report
• Positive Sentiment: The company said management will participate in the Jefferies Global Healthcare Conference, which can raise visibility with investors and potential partners. Conference announcement
• Neutral Sentiment: B. Riley Financial lowered its price target to $10 from $12 but kept a Buy rating. The cut is a mild headwind, but the unchanged bullish rating limits the downside impact. Benzinga report

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Bank of America Corp DE boosted its stake in shares of Orchestra BioMed by 42.0% during the fourth quarter. Bank of America Corp DE now owns 23,780 shares of the company’s stock valued at $95,000 after purchasing an additional 7,036 shares during the period. Creative Planning bought a new position in shares of Orchestra BioMed during the second quarter valued at approximately $40,000. XTX Topco Ltd purchased a new position in shares of Orchestra BioMed in the 2nd quarter valued at $45,000. Marshall Wace LLP purchased a new position in Orchestra BioMed in the second quarter valued at about $133,000. Finally, NewEdge Advisors LLC purchased a new position in shares of Orchestra BioMed in the 2nd quarter worth approximately $118,000. Hedge funds and other institutional investors own 53.20% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on OBIO. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 target price on shares of Orchestra BioMed in a research report on Thursday, March 12th. B. Riley Financial reduced their target price on shares of Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday. Weiss Ratings cut Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Wall Street Zen downgraded shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Barclays boosted their target price on Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $13.60.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.